Demographic details of subjects included in the study
| Asthma (n=35) | Healthy (n=23) | |
| Age | 46.1 (14.4) | 50.8 (14.0) |
| Gender (M/F) | 17/18 | 10/13 |
| BMI, kg/m2 | 28.6 (4.9) | 26.2 (3.4) |
| % predicted FEV1 | 91.5 (22.1)* | 109.8 (17.7) |
| % predicted FVC | 106.0 (14.4) | 112.6 (16.2) |
| FEV1/FVC | 0.71 (0.11)* | 0.79 (0.06) |
| Exhaled nitric oxide, ppb | 29.2 (22.6) | NA |
| Treatment (n) | ||
| As required, bronchodilators only | 10 | NA |
| ICS only | 11 | NA |
| Combination inhalers | 14 | NA |
| Daily inhaled steroid dose, mcg (beclomethasone dose equivalent) | 568.6 (756.1) | NA |
| Sputum cell profile† | ||
| ≥2% eos, ≥40% neuts | 22.2% | NA |
| ≥2% eos, <40% neuts | 22.2% | NA |
| <2% eos, ≥40% neuts | 33.3% | NA |
| <2% eos, <40% neuts | 22.2% | NA |
Data shown as mean (SD) except where indicated.
* p<0.05 versus healthy controls.
† n=18.
eos, eosinophils; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ICS, inhaled corticosteroids; neuts, neutrophils.